The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Pfizer’s Second Biosimilar of J&J’s Remicade Wins U.S. FDA Approval

Pfizer’s Second Biosimilar of J&J’s Remicade Wins U.S. FDA Approval

December 14, 2017 • By Tamara Mathias

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—The U.S. Food and Drug Administration approved Pfizer Inc’s second biosimilar to Johnson & Johnson’s blockbuster rheumatoid arthritis drug, Remicade, the company said on Wednesday.

You Might Also Like
  • FDA Approves Biosimilar to J&J’s Remicade for Multiple Diseases
  • Pfizer Files Suit Against J and J over Remicade Contracts
  • FDA Advisory Panel Strongly Backs Biosimilar Form of Remicade
Also By This Author
  • FDA Staff Raises Safety Concerns Over Arthritis Drug Baricitinib

Pfizer’s Ixifi was approved for all eligible indications of Remicade, including the treatment of bowel disease Crohn’s disease and skin disorder plaque psoriasis, the drugmaker said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Biosimilars are medicines deemed highly similar to an original drug and are seen as cheaper alternatives to biologic products.

With the approval, Ixifi joins the ranks of other biosimilars that have claimed market share from Remicade, including Pfizer and Celltrion Inc’s Inflectra launched in late 2016, and Renflexis, made by Merck & Co and South Korea’s Samsung Bioepis Co Ltd.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pfizer acquired Inflectra when it bought Illinois-based Hospira in 2015. At the time, the drugmaker elected not to discontinue development of Ixifi, which was already underway.

But the company has no plans to commercialize Ixifi, it told Reuters.

“We are currently evaluating our strategic options for Ixifi. But we are continuing to commercialize Inflectra in the U.S.,” a Pfizer spokesman said.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Ixifi comes with the same boxed warning as Remicade, cautioning against the risk of serious infections and malignancy.

Remicade is Johnson & Johnson’s bestselling drug and raked in revenues of $1.65 billion in the latest quarter.

 

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: biosimilar, Johnson & Johnson, Pfizer Inc., Pfizer's Ixifi, REMICADE (infliximab)

You Might Also Like:
  • FDA Approves Biosimilar to J&J’s Remicade for Multiple Diseases
  • Pfizer Files Suit Against J and J over Remicade Contracts
  • FDA Advisory Panel Strongly Backs Biosimilar Form of Remicade
  • Samsung Bioepis Receives Final European Approval for Its Remicade Copy

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)